90th European Atherosclerosis Society Congress 2022
Real-world use of PCSK9 inhibitors: latest insights
News from the European Atherosclerosis Society 90th Congress, 22-25 May 2022, Milan, Italy Alirocumab or evolocumab showed a comparable efficacy and safety profile as that reported in clinical trials, according to a meta-analysis of over 28,000 patients prescribed either PCSK9 inhibitor in a real-world clinical…
read more »
EAS FH Studies Collaboration: missed opportunities to identify FH early
News from the European Atherosclerosis Society 90th Congress, 22-25 May 2022, Milan, Italy Familial hypercholesterolaemia (FH) is characterised by high cholesterol levels from birth, which if untreated confer a risk of accelerated atherosclerotic cardiovascular disease (1). Early identification of children with FH and initiation of…
read more »
Why combination LDL-lowering therapy is mandated by guidelines for very high-risk patients: Insights from DA VINCI
News from the European Atherosclerosis Society 90th Congress, 22-25 May 2022, Milan, Italy According to a simulation study using the DA VINCI data (1), combination LDL-lowering therapy including a PCSK9 inhibitor would result in ~90% of very high-risk patients achieving LDL cholesterol goal, as defined…
read more »
ETESIAN: Phase 2b trial of PCSK9 antisense oligonucleotide
News from the European Atherosclerosis Society 90th Congress, 22-25 May 2022, Milan, Italy In this study, AZD8233 (ION 449) reduced LDL cholesterol by over 70% on top of statin in patients with dyslipidaemia. The findings follow an initial report at the American College of Cardiology…
read more »
